Accepted Manuscript Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs Shadia A. Galal, Ass. Prof. of Organic Chemistry, Ahmed S. Abdelsamie, Samia A. Shouman, Yasmin M. Attia, Hamed I. Ali, Ashraf Tabll, Reem El-Shenawy, Yasmine S. El Abd, Mamdouh M. Ali, Abeer E. Mahmoud, Abeer H. Abdel-Halim, Amal A. Fyiad, Adel S. Girgis, Hoda I. El-Diwani PII: S0223-5234(17)30234-9 DOI: 10.1016/j.ejmech.2017.03.090 Reference: EJMECH 9387 To appear in: European Journal of Medicinal Chemistry Received Date: 9 December 2016 Revised Date: 12 March 2017 Accepted Date: 26 March 2017 Please cite this article as: S.A. Galal, A.S. Abdelsamie, S.A. Shouman, Y.M. Attia, H.I. Ali, A. Tabll, R. El-Shenawy, Y.S. El Abd, M.M. Ali, A.E. Mahmoud, A.H. Abdel-Halim, A.A. Fyiad, A.S. Girgis, H.I. El- Diwani, Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs, European Journal of Medicinal Chemistry (2017), doi: 10.1016/j.ejmech.2017.03.090. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.